



JULY 2023

Does early treatment with highly effective DMT improve prognosis for people with MS?

Thanks so much to the teams in **Stoke, Cincinnati and Mayo** who have contributed to recruitment this month. Along with Cardiff and Cleveland, you have brought the total left to enrol down to only 33! We have received confirmation from PCORI that **we can continue to enrol until 1st April 2024**. We are also now seeing sites collecting their first 48-month data as part of the Long-term Extension study (more on that below).


**33 more
needed!**

LONG-TERM EXTENSION

As you will recall from last month, we have received funding from the National MS Society of the USA to follow DELIVER-MS participants up to Year-6. The study schedule is planned to be even more pragmatic in years 4 to 6 so we hope that sites and participants will consider taking part.

NEWS AND REMINDERS

- ◆ Please do bear in mind the importance of 3-monthly phone calls. Our quality-assurance work tells us that many get missed, which means we miss changes in DMT and adverse events. These are both very important outcomes in the study.



FINAL THOUGHTS:

Thanks for your ongoing support of this trial. Every participant counts now. Thanks again for all your efforts.